Clinician discusses the importance of maximizing medication doses and trial periods for effectively managing tardive dyskinesia at the Southern California Psychiatry Conference.

Maguire discussed the differential diagnosis of bipolar depression at the Southern California Psychiatry Conference.

Yvette Elpidio, PMHNP-BC, shares insights on NMDA agonists at the Southern California Psychiatry conference.

Deb York, PMHNP-BC, sheds light on postpartum psychiatry at the conference.

Discover promising new treatments for schizophrenia, including NBI-1117568 and CPL’36, showcasing significant symptom improvements and safety profiles.

The Chair of the Southern California Psychiatry Conference offers his favorite take home points on schizophrenia and M1-M4 agonists that can be found in the initial sessions.

"Fifteen seconds, thirty, a minute of silence, sweat weeps from the intern’s forehead..."

The new movie "Superman: Legacy" addresses modern social challenges and potential mental health themes.

Brush up on your reading before you attend the Southern California Psychiatry Conference!

Fava beans emerge as a powerful natural source of L-DOPA, offering potential benefits for mood disorders and Parkinson's disease and holding enriching culinary traditions.

Transcend Therapeutic announces breakthrough therapy designation for TSND-201 for treating PTSD.

Learn more about how serum drug levels enhance psychiatric treatment by providing critical insights into medication efficacy and patient outcomes.

The psychological impact of national tragedies: it's time to recognize the importance of mourning and finding meaning in collective grief.

A groundbreaking study links antibiotic exposure to increased depression risk in adolescents, highlighting urinary analysis as a potential screening tool.

Are you ready for new reading recommendations related to psychiatry?

This book explores how mistrust and disinformation shape our beliefs, revealing the psychological mechanisms behind false convictions in today's society.

How can we teach psychopharmacology in a way that engages today's digital-native psychiatry residents and enhances real-world application?

Panelists discuss how viloxazine fits into both pediatric and adult ADHD treatment plans, especially as a non-stimulant option for patients with complex cases or concerns about stimulant side effects, while emphasizing flexible dosing and caregiver involvement.

Panelists discuss how recent clinical studies on viloxazine in children and adolescents demonstrated early symptom improvement, dose-dependent efficacy, and tolerability, with the most benefit seen at 400 mg in those aged 11 and under.

Long COVID presents complex symptoms without clear diagnostic criteria, challenging traditional medical understanding and emphasizing the need for compassionate care.

Johnson & Johnson has submitted an sNDA for Caplyta, showcasing significant relapse prevention in schizophrenia.

Anna Ornstein, MD's legacy as a Holocaust survivor and humanitarian psychiatrist inspires reflection on societal issues and the importance of empathy in healing.